A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes: A randomized, controlled trial

Antzeko izenburuak

• A Novel Insulin Combination of Insulin Degludec and Insulin Aspart Achieves a More Stable Overnight Glucose Profile than Insulin Glargine: Results from Continuous Glucose Monitoring in a Proof-of-Concept Trial
  nork: Liebl, Andreas, et al.
  Argitaratua: (2013)
• Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial
  nork: Kumar, Ajay, et al.
  Argitaratua: (2016)
• Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes: A 26-week, phase 3, randomized, open-label, treat-to-target trial
  nork: Hirsch, Irl B., et al.
  Argitaratua: (2012)
• Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal–bolus treatment in people with Type 1 diabetes: 1–year results from a randomized clinical trial (BOOST (®) T1)
  nork: Hirsch, I. B., et al.
  Argitaratua: (2016)
• Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
  nork: Davis, Sondra, et al.
  Argitaratua: (2017)